Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2)

BACKGROUND: Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM). Acute treatment overuse increases the risk of migraine chronification in patients with HFEM. Galcanezumab, a humanized monoclonal antibody binding c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Headache Pain
Päätekijät: Silberstein, Stephen D., Stauffer, Virginia L., Day, Katie A., Lipsius, Sarah, Wilson, Maria-Carmen
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Springer Milan 2019
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6734504/
https://ncbi.nlm.nih.gov/pubmed/31253091
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-019-1024-x
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia